Most cited papers from Simcyp (United Kingdom)

Simcyp (United Kingdom)

What are the most cited papers from Simcyp (United Kingdom)?

The most cited paper from Simcyp (United Kingdom) is "Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science" (Malcolm Rowland, Carl C. Peck, Geoffrey T. Tucker, 2011), with 656 citations. Next come "Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development" (615) and "Simulation and prediction of in vivo drug metabolism in human populations from in vitro data" (532).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 95 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science Malcolm Rowland, Carl C. Peck, Geoffrey T. Tucker · The Annual Review of Pharmacology and Toxicology Review	6 Jan 2011	656
2	Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development HM Jones, K Rowland‐Yeo · CPT Pharmacometrics & Systems Pharmacology Open access	Aug 2013	615
3	Simulation and prediction of in vivo drug metabolism in human populations from in vitro data Amin Rostami‐Hodjegan, Geoffrey T. Tucker · Nature Reviews Drug Discovery Review	Feb 2007	532
4	The Simcyp ® Population-based ADME Simulator Masoud Jamei, Steve Marciniak, Kairui Feng et al. · Expert Opinion on Drug Metabolism & Toxicology	Feb 2009	530
5	Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children Trevor N. Johnson, Amin Rostami‐Hodjegan, Geoffrey T. Tucker · Clinical Pharmacokinetics	2006	527
6	Population-Based Mechanistic Prediction of Oral Drug Absorption Masoud Jamei, David B. Turner, Jiansong Yang et al. · The AAPS Journal Open access	20 Apr 2009	448
7	Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective Mohamad Shebley et al. · Clinical Pharmacology & Therapeutics Open access	10 Jan 2018	390
8	Adverse outcome pathways: opportunities, limitations and open questions Marcel Leist et al. · Archives of Toxicology Open access	19 Oct 2017	384
9	A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates Masoud Jamei, Gemma L. Dickinson, Amin Rostami‐Hodjegan · Drug Metabolism and Pharmacokinetics	2009	370
10	Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal Pregnancy Khaled Abduljalil, Penny Jayne Furness, Trevor N. Johnson et al. · Clinical Pharmacokinetics	22 Apr 2012	365
11	Prediction of Intestinal First-Pass Drug Metabolism Jiansong Yang, Masoud Jamei, Karen Rowland Yeo et al. · Current Drug Metabolism	Oct 2007	365
12	Changes in liver volume from birth to adulthood: A meta-analysis Trevor N. Johnson, Geoffrey T. Tucker, M. Stuart Tanner et al. · Liver Transplantation Review	28 Nov 2005	329
13	Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology Amin Rostami‐Hodjegan · Clinical Pharmacology & Therapeutics	30 May 2012	328
14	SBML Level 3: an extensible format for the exchange and reuse of biological models Sarah Keating et al. · Molecular Systems Biology Open access142 authors	Aug 2020	316
15	PBPK models for the prediction of in vivo performance of oral dosage forms Edmund S. Kostewicz, Leon J Aarons, Martin Bergstrand et al. · European Journal of Pharmaceutical Sciences	21 Sep 2013	315
16	In vivo methods for drug absorption – Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects Erik Sjögren et al. · European Journal of Pharmaceutical Sciences	19 Mar 2014	277
17	Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data Nikolaos Tsamandouras, Amin Rostami‐Hodjegan, Leon J Aarons · British Journal of Clinical Pharmacology Open access	3 Sep 2013	250
18	Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance Masoud Jamei · Current Pharmacology Reports Open access	14 Apr 2016	245
19	In vitro to in vivo extrapolation for high throughput prioritization and decision making Shannon M. Bell et al. · Toxicology in Vitro Open access	5 Dec 2017	244
20	‘In silico’ simulations to assess the ‘in vivo’ consequences of ‘in vitro’ metabolic drug–drug interactions Amin Rostami‐Hodjegan, Geoff T. Tucker · Drug Discovery Today Technologies	3 Nov 2004	242
21	Cytochrome P450 Turnover: Regulation of Synthesis and Degradation, Methods for Determining Rates, and Implications for the Prediction of Drug Interactions Jiansong Yang, Mingxiang Liao, Magang Shou et al. · Current Drug Metabolism	Jun 2008	241
22	A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance Trevor N. Johnson, Koen Boussery, K Rowland‐Yeo et al. · Clinical Pharmacokinetics	23 Feb 2010	234
23	Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies Miroslav Dostálek, Iain B. Gardner, Brian M. Gurbaxani et al. · Clinical Pharmacokinetics	8 Jan 2013	230
24	Prediction ofin vivodrug clearance fromin vitrodata. I: Impact of inter-individual variability Eleanor M. Howgate, Karen Rowland Yeo, N. J. Proctor et al. · Xenobiotica	Jun 2006	222
25	Expression of Hepatic Drug-Metabolizing Cytochrome P450 Enzymes and Their Intercorrelations: A Meta-Analysis Brahim Achour, Jill Barber, Amin Rostami‐Hodjegan · Drug Metabolism and Disposition Review	31 May 2014	212
26	Animal versus human oral drug bioavailability: Do they correlate? Helen Musther, Andrés Olivares‐Morales, Oliver J. D. Hatley et al. · European Journal of Pharmaceutical Sciences Open access	26 Aug 2013	212
27	Meta-Analysis of the Turnover of Intestinal Epithelia in Preclinical Animal Species and Humans Adam S. Darwich, Umair Aslam, Darren M. Ashcroft et al. · Drug Metabolism and Disposition Review	19 Sep 2014	209
28	ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport-Mediated PK and DDIs in Humans Maciej J. Zamek‐Gliszczynski, C A Lee, Agnès Poirier et al. · Clinical Pharmacology & Therapeutics Open access	25 Feb 2013	195
29	PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals Frédéric Y. Bois, Masoud Jamei, Harvey J. Clewell · Toxicology Open access	Jul 2010	192
30	Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut—The effect of diltiazem on the time-course of exposure to triazolam Karen Rowland Yeo, Masoud Jamei, Jiansong Yang et al. · European Journal of Pharmaceutical Sciences	17 Dec 2009	186
31	Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice Trevor N. Johnson, Amin Rostami‐Hodjegan · Pediatric Anesthesia	22 May 2010	169
32	Simultaneous Quantification of the Abundance of Several Cytochrome P450 and Uridine 5′-Diphospho-Glucuronosyltransferase Enzymes in Human Liver Microsomes Using Multiplexed Targeted Proteomics Brahim Achour, Matthew R. Russell, Jill Barber et al. · Drug Metabolism and Disposition	10 Jan 2014	167
33	A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine Masoud Jamei, F. Bajot, Sibylle Neuhoff et al. · Clinical Pharmacokinetics Open access	24 Jul 2013	161
34	An in vitro toolbox to accelerate anti-malarial drug discovery and development Susan A. Charman et al. · Malaria Journal Open access	2 Jan 2020	160
35	Modeling and predicting drug pharmacokinetics in patients with renal impairment Karen Rowland Yeo, Mohsen Aarabi, Masoud Jamei et al. · Expert Review of Clinical Pharmacology	Mar 2011	159
36	Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations Khaled Abduljalil, Theresa Cain, Helen Humphries et al. · Drug Metabolism and Disposition	3 Jul 2014	148
37	Physiologically‐Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug–Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations Kunal S. Taskar, Venkatesh Pilla Reddy, Howard J. Burt et al. · Clinical Pharmacology & Therapeutics Open access	19 Oct 2019	146
38	Does age affect gastric emptying time? A model‐based meta‐analysis of data from premature neonates through to adults Jennifer J. Bonner, Pavan Vajjah, Khaled Abduljalil et al. · Biopharmaceutics & Drug Disposition Open access	20 Jan 2015	143
39	Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of Drugs Miroslav Dostálek, Fatemeh Akhlaghi, Martina Puzanovova · Clinical Pharmacokinetics	Aug 2012	129
40	Effective exposure of chemicals in in vitro cell systems: A review of chemical distribution models Susana Proença, Beate Isabella Escher, Fabian C. Fischer et al. · Toxicology in Vitro Open access	Mar 2021	129
41	Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling Zoe E. Barter, Geoffrey T. Tucker, K Rowland‐Yeo · Clinical Pharmacokinetics	Jul 2013	129
42	Systems Toxicology: Real World Applications and Opportunities Thomas Härtung, Rex FitzGerald, Paul E. Jennings et al. · Chemical Research in Toxicology Open access	31 Mar 2017	128
43	A Re-evaluation and Validation of Ontogeny Functions for Cytochrome P450 1A2 and 3A4 Based on In Vivo Data Farzaneh Salem, Trevor N. Johnson, Khaled Abduljalil et al. · Clinical Pharmacokinetics	26 Mar 2014	127
44	A pregnancy physiologically based pharmacokinetic (p‐ PBPK ) model for disposition of drugs metabolized by CYP1A2 , CYP2D6 and CYP3A4 Lu Gaohua, Khaled Abduljalil, Masoud Jamei et al. · British Journal of Clinical Pharmacology Open access	22 Jun 2012	124
45	Prediction of time-dependent CYP3A4 drug–drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover Karen Rowland Yeo, Robert L. Walsky, Masoud Jamei et al. · European Journal of Pharmaceutical Sciences	22 Apr 2011	122
46	In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration James Butler et al. · European Journal of Pharmaceutics and Biopharmaceutics Open access	20 Dec 2018	121
47	The Simcyp Population Based Simulator: Architecture, Implementation, and Quality Assurance Masoud Jamei, Steve Marciniak, Duncan L. Edwards et al. · In Silico Pharmacology Open access	3 Jun 2013	121
48	Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug–drug interactions Howard J. Burt, Sibylle Neuhoff, Lisa M. Almond et al. · European Journal of Pharmaceutical Sciences Open access	25 Mar 2016	118
49	Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations Wiebke Albrecht et al. · Archives of Toxicology Open access	Jun 2019	116
50	Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19 Alice Ban Ke, Srikanth C. Nallani, Ping Zhao et al. · British Journal of Clinical Pharmacology Open access	9 Jul 2013	112

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.